Sedano Cecilia D, Sarnow Peter
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.
Semin Liver Dis. 2015 Feb;35(1):75-80. doi: 10.1055/s-0034-1397351. Epub 2015 Jan 29.
It has remained an enigma how hepatitis C viral (HCV) RNA can persist in the liver of infected patients for many decades. With the recent discovery of roles for microRNAs in gene expression, it was reported that the HCV RNA genome subverts liver-specific microRNA miR-122 to protect its 5' end from degradation by host cell exoribonucleases. Sequestration of miR-122 in cultured liver cells and in the liver of chimpanzees by small, modified antisense RNAs resulted in dramatic loss of HCV RNA and viral yield. This finding led to the first successful human trial in which subcutaneous administration of antisense molecules against miR-122 lowered viral yield in HCV patients, without the emergence of resistant virus. In this review, the authors summarize the molecular mechanism by which miR-122 protects the HCV RNA genome from degradation by exoribonucleases Xrn1 and Xrn2 and discuss the application of miR-122 antisense molecules in the clinic.
几十年来,丙型肝炎病毒(HCV)RNA如何在受感染患者的肝脏中持续存在一直是个谜。随着最近发现微小RNA在基因表达中的作用,有报道称HCV RNA基因组会利用肝脏特异性微小RNA miR-122来保护其5'端不被宿主细胞外切核糖核酸酶降解。在培养的肝细胞和黑猩猩肝脏中,通过小型修饰反义RNA隔离miR-122,导致HCV RNA和病毒产量大幅下降。这一发现促成了首例成功的人体试验,皮下注射针对miR-122的反义分子可降低HCV患者的病毒产量,且未出现耐药病毒。在这篇综述中,作者总结了miR-122保护HCV RNA基因组不被外切核糖核酸酶Xrn1和Xrn2降解的分子机制,并讨论了miR-122反义分子在临床上的应用。